Novartis India Ltd

• 

  NeoBiocon Partners Novartis to Launch Diabetes Drugs in UAE

  NeoBiocon, a collaboration between Biocon Ltd and BR Shetty led UAE-based Neopharma, has partnered with Novartis Middle East FZE to market diabetes drugs Jalra and Jalra-M in the UAE.

• 

  Drug Pricing: Don't Take Coercive Steps Against Cipla, Others, Says Court

  The Delhi High Court on Tuesday told the government not to take any coercive action against pharmaceutical companies including Novartis India Limited and Cipla Ltd in connection with the notices issued to them for allegedly not ensuring implementation of the revised drug pricing of 2013.

• Novartis Posts Loss of Rs 1.18 Crore in Q3

  Drugmaker Novartis India Ltd on Wednesday reported a net loss of Rs 1.18 crore for the third quarter that ended on December 31, 2014.

• Novartis Okays OTC Unit Sale to GSK Consumer

  The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.

• 

  Novartis-GSK Pharma Deal Cleared by CCI

  The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.

• Novartis Posts 69 Per Cent Decline in Q2 Profit

  Drug firm Novartis India on Friday registered a 69.14 per cent decline in net profit at Rs 14.04 crore for the quarter ended September 2014.

• 

  Drug Pricing Regulator Slaps Rs 300 Crore Penalty on Novartis: Report

  Drug major Novartis has been slapped with a Rs 300 crore penalty by the National Pharmaceutical Pricing Authority (NPPA) for overcharging consumers on sale of Voveran, its best-selling painkiller.

• Delhi High Court Asks Pharma Companies, Centre to Resolve the Drug Pricing

  A bench of Justice B D Ahmed and Justice Vibhu Bakhru said representatives of the pharma companies hold a meeting with the Director of the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, to settle the matter "once and for ever".

• GSK says Novartis deal not to impact India business

  The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.

• Big Pharma pushes for US action against India over patent worries: report

  Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

• Nine companies offer to sell shares via OFS, six succeed

  While six of them, including Tata Comm, Rama Phosphates, Marathwada Refractories, saw their OFS getting oversubscribed, the issues of BGR Energy Systems, Essar Ports and Omaxe could not get full subscription for the shares under offer, as per data with the bourses.

• Companies to seek extension of June deadline, easing norms from Sebi

  With less than two months left for lowering their promoter holding to 75 per cent, many private sector companies are planning to petition Sebi to relax the norms -- either by way of a deadline extension or relaxation in the compliance procedures.

• Big Pharma down, not out, after Novartis patent blow

  Stung by a landmark patent defeat, Western drug-makers will be wary about launching new products in India, but they cannot afford to quit a country tipped to be the world's eighth largest market for medicines by 2016.

• Novartis loses landmark India patent case on Glivec

  The Supreme Court dismissed Swiss drug-maker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

• Pharma giant Novartis waits nervously on Glivec drug patent verdict today

  Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country.